ArticleJournal of the American Heart Association2026
Development and Validation of a Machine Learning Model for Incident Heart Failure Prediction in Chronic Kidney Disease: A Multicenter Cohort Study.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) and heart failure (HF) share pathophysiological mechanisms, rendering HF one of the most burdensome cardiovascular complication in CKD. Current HF prediction models, derived from the general population, exhibit limited accuracy in CKD, thus necessitating a CKD-specific risk model and clinical implementation.
methodsThe development set comprised 52 251 patients with CKD from the China Renal Data System (70% training; 30% internal validation). External validation used 21 798 patients from independent Chinese hospitals and 3323 UK Biobank participants. Outcome was 5-year new-onset HF. Five machine learning models were developed, with performance assessed via area under the curve and compared using DeLong test. The top-performing extreme gradient boosting model was simplified via forward stepwise selection; feature importance quantified using Shapley additive explanations.
resultsIn the Chinese external validation cohort, the extreme gradient boosting model outperformed others (area under the curve, 0.879 [95% CI, 0.871-0.887]; DeLong
conclusionsThe 9-variable extreme gradient boosting model tailored for patients with CKD may help predict HF risk in this high-risk population. Validation across diverse populations is warranted to confirm its generalizability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.